Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06788535 · ClinicalTrials.gov registry record · Phase 3

Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

A Phase 3 study of Cardiac Amyloidosis, sponsored by Sharmila Dorbala.

Active
Registry status
Phase 3
Development phase
200
Enrollment target
20
Study locations

NCT06788535 is a Phase 3 study of Cardiac Amyloidosis that is active but no longer recruiting, run by Sharmila Dorbala. The registered enrollment target is 200 participants, below the 930-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06788535, a Phase 3 study of Cardiac Amyloidosis, is active but no longer recruiting, sponsored by Sharmila Dorbala.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emission Tomography Computed Tomography (PET/CT) scan.

Conditions Studied

Cardiac Amyloidosis

Interventions

  • DRUG I-124 evuzamitide

Study Locations (20)

California

  • City of Hope - Duarte - Duarte
  • University of California - San Francisco

Illinois

  • Northwestern University - Chicago
  • Cook County Health - Chicago

Missouri

  • St. Lukes (CVIT) Saint Luke's Health System - Kansas City
  • Washington University of St. Louis - St Louis

North Carolina

  • Duke University - Durham
  • Cone Health - Greensboro

Arizona

  • Mayo Clinic - Scottsdale

Connecticut

  • Yale Cardiovascular Medicine - New Haven

Florida

  • Cleveland Clinic - Weston

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-01-14
Est. Completion 2026-02-13
Phase Phase 3

Sponsor

Sharmila Dorbala

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06788535

The ClinicalTrials.gov registry entry for NCT06788535 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 930-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (78% lower). The listed sponsor is Sharmila Dorbala, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which I-124 evuzamitide is the first listed.

NCT06788535 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT06788535 about?

NCT06788535 is a clinical study titled "Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis". The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emiss...

What is the current status of trial NCT06788535?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-01-14. Estimated completion is 2026-02-13.

What conditions does trial NCT06788535 study?

This clinical trial studies the following conditions: Cardiac Amyloidosis.

What interventions are being tested in trial NCT06788535?

The interventions under investigation include: I-124 evuzamitide (DRUG).

Who is sponsoring clinical trial NCT06788535?

This trial is sponsored by Sharmila Dorbala, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06788535 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cardiac Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cardiac Amyloidosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.